Nurix Therapeutics

1700 Owens Street
Suite 205
San Francisco
California
94158
United States

Tel: 415-660-5320

About Nurix Therapeutics

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.

Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.

99 articles about Nurix Therapeutics

Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

7/13/2021

Nurix Therapeutics Inc. today reported financial results for the second quarter ended May 31, 2021 and provided a corporate update.
Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development

6/21/2021

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff has joined the company as chief operating officer and executive vice president of product development
Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease

6/2/2021

Data were presented at the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress
Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors

6/1/2021

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Clay Siegall, Ph.D., to its board of directors.
Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual CongressNX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a model of autoimmune disease

5/21/2021

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced that preclinical data from its NX-5948 program will be presented at the upcoming European Alliance of Associations for Rheumatology 2021 Virtual Congress, which will be held June 2−5, 2021.
Nurix Therapeutics to Participate in Upcoming Investor Conferences - May 11, 2021

5/11/2021

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced that members of Nurix management team will participate in the following conferences in May
Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

4/13/2021

Nurix Therapeutics Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the first quarter ended February 28, 2021 and provided a corporate update.
Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

4/7/2021

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced that Arthur T. Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14th, 2021 at 11:45 a.m. ET.
Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers

3/16/2021

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it is part of a collaboration sponsored by Alex’s Lemonade Stand Foundation (ALSF), a leading funder of pediatric cancer research, to develop a drug to potentially treat aggressive childhood cancers including neuroblastoma and medulloblastoma
Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR

3/10/2021

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced presentation of data from its NX-1607 program at the American Association for Cancer Research 2021 annual meeting which is being held virtually over two weeks, April 10-15 and May 17-21.
Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences

3/9/2021

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate and present at the following conferences in March: Guggenheim Targeted Protein Degradation Day Virtual Conference Tuesday, March 16, 2021 10:30 - 11:30 AM EDT
Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

3/9/2021

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its underwritten public offering of 5,175,000 shares of its common stock at a public offering price of $31.00 per share, which includes 675,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock

3/2/2021

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock.
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update

2/16/2021

First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies Three additional wholly owned programs expected to enter clinical trials in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Year-end cash and investments totaling $372 million
Biopharma Companies Entering 2021 With New Collabs, Partnerships

1/8/2021

Here’s a run-down of some of the most recent collaboration announcements this week.
Nurix Therapeutics Announces Presentation at 39th Annual J.P. Morgan Healthcare Conference

1/5/2021

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 3:40 p.m. EST. The presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website
Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and ExpositionData support a planned clinical trial of NX-2127 in B-cell malignancies

12/7/2020

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of key preclinical data from its lead program, NX-2127, for the potential treatment of B-cell malignancies, at the 62 nd American Society of Hematology (ASH) Annual Meeting and Exposition. Supported by these data, Nurix plans to initiate a Phase 1 clinical trial of orally administered NX-2127 in
Nurix Therapeutics to Present at Upcoming Investor Conferences

11/9/2020

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced that it will be presenting at the following healthcare investor conferences
Nurix Therapeutics Announces Appointment of Robert Tjian as Chairman of Scientific Advisory Board and His Resignation from the Board of Directors

10/26/2020

Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to lead Nurix’s Scientific Advisory Board, Robert Tjian, Ph.D. has resigned from the Company’s Board of Directors effective November 1, 2020
Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update

10/14/2020

Nurix Therapeutics Inc. (Nasdaq: NRIX), a biotechnology company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2020 and provided a corporate update. Recent Business Highlights Strengthened Leadership Team with Key Appointments . Added Dr. Mich